Your browser doesn't support javascript.
loading
Phenotype standardization for statin-induced myotoxicity.
Alfirevic, A; Neely, D; Armitage, J; Chinoy, H; Cooper, R G; Laaksonen, R; Carr, D F; Bloch, K M; Fahy, J; Hanson, A; Yue, Q-Y; Wadelius, M; Maitland-van Der Zee, A H; Voora, D; Psaty, B M; Palmer, C N A; Pirmohamed, M.
Afiliação
  • Alfirevic A; Department of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Neely D; Department of Clinical Biochemistry, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Armitage J; Clinical Trial Service Unit, Oxford, UK.
  • Chinoy H; Centre for Musculoskeletal Research/NIHR Manchester Musculoskeletal Biomedical Research Unit, University of Manchester, Manchester, UK.
  • Cooper RG; MRC/ARUK Institute of Ageing and Chronic Disease, Faculty of Health & Life Sciences, University of Liverpool, Liverpool, UK.
  • Laaksonen R; Zora Biosciences Ltd, Tieotie 2, Espoo, Finland.
  • Carr DF; Department of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Bloch KM; Department of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Fahy J; Department of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Hanson A; Department of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Yue QY; The Medical Products Agency, Uppsala, Sweden.
  • Wadelius M; Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Maitland-van Der Zee AH; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
  • Voora D; Duke Institute for Genome Sciences and Policy, Durham, North Carolina, USA.
  • Psaty BM; 1] Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, Washington, USA [2] Group Health Research Institute, Group Health Cooperative, Seattle, Washington, USA.
  • Palmer CN; Medical Research Institute, Ninewells Hospital and Medical School, Dundee, UK.
  • Pirmohamed M; Department of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Clin Pharmacol Ther ; 96(4): 470-6, 2014 Oct.
Article em En | MEDLINE | ID: mdl-24897241
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Doenças Musculares Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Doenças Musculares Idioma: En Ano de publicação: 2014 Tipo de documento: Article